The pso Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the pso Hub cannot guarantee the accuracy of translated content. The pso and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The PsOPsA Hub is supported by educational grants. All educational content is developed independently by SES in collaboration with our expert steering committee, with no input or influence from financial supporters. We would like to express our gratitude to the following companies for their support: • UCB: For website development, launch, and ongoing maintenance. • UCB: For educational content and news updates.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View pso content recommended for you
Vaccination recommendations for patients with psoriatic disease receiving oral and biologic therapies
Individuals with moderate-to-severe psoriasis and/or psoriatic arthritis are at an increased risk of infection. However, guidance is required to understand how to best manage vaccination alongside systemic psoriasis treatment.
Here, we summarize recommendations by Chat et al. published in Journal of the American Academy of Dermatology, on the use of biologics and oral treatments in patients with psoriatic disease receiving vaccinations.
Methods1
-
A literature review of articles published in PubMed from 1950–2022 that included the terms ‘vaccine’ or ‘vaccination’ and each systemic therapy approved for psoriasis or psoriatic arthritis was conducted and used to develop 22 consensus statements through a modified Delphi process.
-
Overall, 30 members of the National Psoriasis Foundation and COVID-19 Task Force voted to report their level of agreement with each statement.
-
Where there was insufficient data, recommendations were developed using expert opinion.
Key findings1
-
Overall, 22 consensus statements were agreed for oral (Figure 1) and biologic (Figure 2) therapies.
-
In general, recommendations state that:
-
-
non-live vaccines can be given without disruption to oral or biologic therapy, apart from methotrexate; and
-
oral or biologic therapy should be discontinued before and after live vaccination.
-
-
Recommendations could not be given for the use of vaccines with phototherapy due to a lack of available clinical data.
Figure 1. Vaccine recommendations for patients receiving oral therapies*
*Data from Chat, et al.1 Created with BioRender.com.
Figure 2. Vaccine recommendations for patients receiving biologic therapies*
IL, interleukin; TNF, tumor necrosis factor.
*Data from Chat, et al.1 Created with BioRender.com.
|
Key learnings |
|
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content